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Abstract 
Obesity increases preeclampsia risk and maternal dyslipidaemia may result from exaggerated 
adipocyte lipolysis. We compared adipocyte function in preeclampsia with healthy pregnancy 
to establish if there is increased lipolysis. Subcutaneous and visceral adipose tissue biopsies 
were collected at Caesarean section from healthy (n=31) and preeclampsia (n=13) mothers. 
Lipolysis in response to isoproterenol (200nM) and insulin (10nM) was assessed. In healthy 
pregnancy, subcutaneous adipocytes had higher diameter than visceral adipocytes (P<0.001). 
Subcutaneous and visceral adipocyte mean diameter in preeclampsia was similar to that in 
healthy pregnant controls but cell distribution was shifted towards smaller cell diameter in 
preeclampsia. Total lipolysis rates under all conditions were lower in healthy visceral than 
subcutaneous adipocytes but did not differ after normalization for cell diameter. Visceral 
adipocyte insulin sensitivity was lower than subcutaneous in healthy pregnancy and inversely 
correlated with plasma triglyceride (r=-0.50, P=0.004). Visceral adipose tissue had lower 
ADRB3, LPL and leptin and higher insulin receptor messenger RNA expression than 
subcutaneous adipose tissue. There was no difference in subcutaneous adipocyte lipolysis 
rates between preeclampsia and healthy controls but subcutaneous adipocytes had lower 
sensitivity to insulin in preeclampsia, independent of cell diameter (P <0.05). In 
preeclampsia, visceral adipose tissue had higher LPL messenger RNA expression than 
subcutaneous. In conclusion, in healthy pregnancy, the larger total mass of subcutaneous 
adipose tissue may release more fatty acids into the circulation than visceral adipose tissue. 
Reduced insulin-suppression of subcutaneous adipocyte lipolysis may increase the burden of 
plasma fatty acids that the mother has to process in preeclampsia.  
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Introduction 
Maternal metabolism during pregnancy adapts to support fetal growth and development. All 
women increase maternal fat stores in early pregnancy in order to meet the feto-placental and 
maternal metabolic demands of late gestation and lactation1, 2.  Total fat increases to a peak 
toward the end of the second trimester before diminishing, corresponding to a period of 
increased lipolytic activity3-5.  In women of normal weight, the majority of fat is accumulated 
centrally in the subcutaneous compartment of the trunk and upper thigh6, 7. In later stages of 
pregnancy there is an increase in both the thickness of pre-peritoneal fat (visceral) and the 
ratio of  pre-peritoneal to subcutaneous fat as measured by ultrasound8. This pattern may be 
related to the increasing gestational insulin resistance and hyperlipidaema. Hepatic fat is an 
important mediator of gestational insulin resistance in the rat9 and has also been suggested to 
be important in humans10. Visceral adiposity correlates with metabolic risk factors11 and 
adverse metabolic outcomes in pregnancy including gestational diabetes mellitus, and 
preeclampsia (PE)12-14.  
 
PE occurs in 2-4% of all pregnancies and is a leading cause of maternal and neonatal 
morbidity and mortality. There is considerable evidence that maternal obesity, increased 
insulin resistance and aberrant fatty acid metabolism are involved in the pathogenesis of PE15. 
There is a marked increase in plasma triglyceride concentration and an early rise in plasma 
non-esterified fatty acids (NEFA), independent of adiposity, suggesting exaggerated 
adipocyte lipolysis15. Adipocyte lipolysis in the non-pregnant is under adrenergic control with 
ADRB1, ADRB2 and ADRB3 receptors stimulating catecholamine-mediated lipolysis and 
ADRA2A mediating its inhibition. Fatty acids are released from cellular triglyceride droplets 
by the sequential action of adipose tissue triglyceride lipase (ATGL) and hormone sensitive 
lipase (HSL). This latter enzyme is sensitive to insulin and is the mechanism by which insulin 
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suppresses lipolysis. Elevated plasma NEFA levels and/or increased flux can contribute to 
insulin resistance, endothelial dysfunction and inflammation, all key features of PE10.  
Adipocytes store triglyceride using fatty acids released from plasma lipoproteins by the 
enzyme lipoprotein lipase (LPL). The hormone leptin is secreted by adipocytes and is 
involved in regulation of body weight and energy expenditure as well has regulating other 
metabolic and inflammatory pathways. It interacts with leptin receptors which exist as short 
and long isoforms16. 
 
Despite the relevance of adipose tissue and adipocyte function to both normal and 
complicated pregnancy metabolism, there has been little direct study of adipocytes in human 
pregnancy. We hypothesized that adipocytes in PE are more susceptible to lipolysis and 
contribute to the increased NEFA seen in this condition. The aim of this study was to 
compare the lipolytic function of both visceral adipose tissue (VAT) and upper body 
subcutaneous adipose tissue (SAT) adipocytes under basal conditions, after isoproterenol 
stimulation, after inhibition with insulin, and also in the presence of both isoproterenol and 
insulin to assess the insulin sensitivity of the lipolytic response in healthy human pregnancy 
and in PE. The expression of genes relevant to lipolysis and its regulation were also studied 
in tissue biopsies. 
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Methods 
Subject recruitment 
Non-labouring healthy women at term (n=31) and women with PE undergoing Caesarean 
section (n=13) were recruited from the Princess Royal Maternity Hospital, Glasgow. Age- 
and body mass index (BMI)-matched controls (2 controls per case) were selected from the 
healthy cohort. The study was approved by the Local Research Ethics Committee and all 
women gave written informed consent. Details of selection criteria, patient data collection 
and tissue sampling are provided in the online Data Supplement.  
 
Plasma metabolites 
Plasma total cholesterol, triglyceride and high density lipoprotein (HDL) cholesterol17, 
glucose and high sensitivity C-reactive protein (CRP) assays18 were performed by the 
Department of Clinical Biochemistry, Glasgow Royal Infirmary by routine methods. Other 
analytes were assayed using commercially available kits (online Data Supplement). HOMA 
was calculated as follows: [fasting insulin (mU/L) x fasting glucose (mmol/L)]/22.5. 
 
Adipocyte preparation, sizing and DNA content 
Adipocyte preparation used a modification Rodbell et al19, and detail is provided in the online 
Data Supplement. Adipocytes were resuspended at approximately 90% cytocrit. The 
diameters of 100 adipocytes were manually measured using a stage micrometer and a mean 
calculated for each preparation. DNA was isolated from a known volume of adipocytes using 
the Blood Prep DNA Purification protocol on the ABI PrismTM  6100 Nucleic Acid 
PrepStation (Applied Biosystems). The concentration of DNA was quantified using a 
Nanodrop® ND 100.  
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Adipose tissue lipolysis assay 
Adipocyte cell suspension (100ul) was assayed in a final volume of 1 mL as described in the 
online Data Supplement. The following conditions were included: basal lipolysis (no 
reagent), isoproterenol (200nM), insulin (Human Actrapid® Novo Nordisk, 10nM), and 
combined isoproterenol (200nM) and insulin (10nM). Glycerol and NEFA concentrations 
were quantitated by colorimetric assay (Randox Laboratories Ltd, Co Antrim, UK and Wako 
NEFA-C; Alpha laboratories, Eastleigh, Hampshire, UK respectively). Adipocyte cell 
number was measured indirectly by quantifying the DNA content in a known volume of 
adipocyte suspension and expressing lipolysis rates as umol/L NEFA or glycerol released per 
ug of DNA. The degree of stimulation by isoproterenol and the degree of suppression by 
insulin was calculated as a percentage of basal release of NEFA or glycerol. Fat cell insulin 
sensitivity index (FCISI) was calculated as the percentage inhibition of isoproterenol-
stimulated lipolysis by insulin.  
 
Adipose tissue mRNA expression quantitation 
Total RNA was isolated from adipose tissue and cDNA synthesized. Target gene expression 
was quantitated relative to a control gene by Taqman real time PCR using commercial primer 
probes sets (Applied Biosystems), see online Data Supplement.  
 
Statistical Analysis  
Data was assessed for normal distribution using a Ryan-Joiner test and transformed to 
achieve a normal distribution where necessary. Means with standard deviation (SD) are 
presented. Comparison within individuals was by paired t test (SAT vs VAT) and between 
PE and controls by two sample t-test. Mann-Whitney and Chi-squared tests were used to test 
between differences in semi-categorical and categorical variables respectively. P <0.05 was 
considered significant. Cell diameters were divided into tertiles and differences in distribution 
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among tertiles between control and PE were tested by Chi-squared test. Pearson’s correlation 
coefficients were calculated to assess associations between variables and r value and P-value 
stated (P d0.010 was considered significant due to multiple testing). The data was adjusted 
for potential cofounders using the General Linear Model. Regression modelling used 
stepwise regression with p-to-enter and p-to-stay set at 0.15. Best models with significant 
predictive variables (P <0.05) are shown. All statistical analysis was carried out in Minitab 
(version 16). 
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Results 
Maternal demographic and biochemical profile 
PE women had similar smoking rates to controls, were more likely to be primiparous, had 
higher systolic and diastolic blood pressure, delivered at an earlier gestation and had 
offspring of lower bith weight centile (BWC) (Table 1). PE mothers had higher plasma 
triglyceride and NEFA and lower placental lactogen concentrations than matched controls. 
 
SAT and VAT cell size in healthy and PE pregnancy 
SAT adipocytes were 23um larger in diameter than VAT adipocytes (P<0.001) (Table 1). 
SAT and VAT cell sizes were correlated with each other (r=0.72, P <0.001) and also with 
maternal BMI (SAT r=0.46 P=0.010, VAT r=0.55 P=0.001) and plasma leptin (SAT r=0.51 
P=0.003, VAT r=0.51 P=0.004). Neither SAT nor VAT cell diameter differed between 
control and PE pregnancies (Table 1). A significant difference in the SD of the 100 SAT cell 
diameters collected for each individual in the control group and the PE group (control 1.32 vs 
PE 1.26 um, P=0.033) suggested that the distribution of cell size may differ between groups. 
When cell diameter distribution among tertiles of diameter was compared between PE and 
controls (Figure S1), it was seen that diameter distribution was shifted toward smaller 
diameter for SAT (P=0.004) and VAT (P=0.019) in PE adipocyte preparations. In PE there 
was a correlation between SAT and VAT diameter (r=0.79, P=0.001). Maternal BMI, but not 
plasma leptin, was correlated with SAT (r=0.73, P=0.005) and VAT (r=0.84, P <0.001) 
diameter in PE. 
 
SAT and VAT lipolytic function in healthy pregnancy 
Total lipolysis rates under all conditions were lower in VAT than SAT (Table 2) and net 
basal lipolysis rate was lower in VAT. VAT net lipolysis was more responsive to stimulation 
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by isoproterenol than SAT. VAT had lower net lipolysis FCISI than SAT (Table 2). In SAT 
and VAT, basal total and basal net lipolysis rates were inversely correlated with percent 
stimulation by isoproterenol (r=-0.55 to -0.79, Pd0.001). In SAT only, net basal lipolysis rate 
was positively correlated with percent suppression by insulin (r=0.62, P <0.001). When cell 
diameter was included as a covariate in a General Linear Model, adipose tissue depot location 
was no longer a significant predictor of total or net lipolysis rates while cell diameter was 
(P<0.05), apart from isoproterenol-stimulated lipolysis where neither was associated. Cell 
diameter was significantly associated with percent stimulation of total basal lipolysis by 
isoproterenol (P<0.05).  
 
The ratio of NEFA to glycerol released during lipolysis significantly decreased on exposure 
to isoproterenol and/or insulin in SAT but not VAT (Figure S2). However there were no 
significant differences in the NEFA/glycerol ratio between SAT and VAT under any 
condition.  For VAT, but not SAT, recycling was correlated with cell size under basal 
(r=0.46, P=0.009) and isoproterenol-stimulated conditions (r=0.56, P=0.001).  
 
There was no correlation between any measure of either SAT or VAT lipolytic function and 
maternal BMI, age, parity, blood pressure, offspring birth weight and BWC. VAT net 
lipolysis FCISI was inversely correlated with plasma triglyceride (r=-0.50, P=0.004) 
concentrations but there were no univariate associations of SAT or VAT lipolytic activity 
with glucose, insulin, HOMA or leptin.  
 
SAT and VAT receptor and enzyme expression in healthy pregnancy 
There was no difference in adrenoceptor A2A, B1 and B2 expression but VAT had 79% 
(P=0.036) lower ADRB3 mRNA expression than SAT (Figure 1). LPL mRNA expression 
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was 30% lower (P=0.010) and leptin mRNA expression was 57% lower (P<0.001) in VAT 
than SAT. Insulin receptor had 62% (P=0.027) higher expression in VAT than SAT.  
Expression of the long form of the leptin receptor was undetectable in SAT whereas low 
levels of expression were seen in VAT. None of the receptor or enzyme expression levels that 
differed between VAT and SAT was correlated with maternal BMI, plasma leptin or rates of 
lipolysis or FCISI. 
 
Stepwise regression was carried out to identify whether the expression of enzymes or 
receptors was associated with SAT FCISI in controls. In healthy SAT, neither cell size nor 
any enzyme or receptor expression was associated with net lipolysis FCISI, whereas ADRB1 
(P=0.032) and LPL (P=0.043) expression were negatively associated with total lipolysis 
FCISI (r2 adjusted 46%), independent of cell diameter.  
 
Adipose tissue lipolytic function, receptor and enzyme expression in PE 
There were no differences in SAT total or net lipolysis rates between women with PE and 
age- and BMI-matched controls (Table 3). In PE, SAT had a lower net FCISI than controls. 
In univariate analysis maternal BMI, SAT cell size and progesterone were found to have an 
association with SAT total, but not net, lipolysis FCISI. When these factors were included in 
a General Linear Model, SAT total FCISI was now significantly different between PE           
(-118%) and controls (37%), P=0.012. There were no differences in VAT lipolytic function 
between PE and control women apart from a lower NEFA/glycerol ratio in the presence of 
isoproterenol and insulin in PE (Figure S3). There were no differences in mRNA expression 
of any of the measured receptors or enzymes in SAT, although there was a trend towards a 
154% higher LIPE expression in PE (p=0.059) (Figure 2). In VAT there was 45% increased 
expression of LPL (P=0.022).  
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Regulation of SAT and VAT lipolysis in healthy pregnancy 
Stepwise multiple regression was carried out to determine the contribution of cell size, 
plasma estradiol, placental lactogen, HOMA, leptin, adiponectin and tumour necrosis factor 
(TNF) ± on basal lipolysis and FCISI in SAT and VAT from healthy pregnancy (Table S1). 
In initial modelling progesterone was not associated with lipolytic function. SAT basal net 
and total lipolysis was significantly associated with TNF±, whereas in VAT net lipolysis was 
associated with cell diameter and HOMA with placental lactogen a non-significant 
contributor to the model. In healthy SAT a number of variables contributed to FCISI. 
Estradiol was negatively associated with total FCISI, and cell diameter negatively and leptin 
and TNF± positively associated with net FCISI. In VAT estradiol (negatively) and placental 
lactogen were associated with FCISI with HOMA making an additional negative contribution 
to net FCISI.  
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Discussion 
In PE, SAT adipocyte insulin sensitivity was lower than in matched controls. This is the first 
direct evidence that PE is associated with increased lipolysis at maternal adipocytes and 
could explain the exaggerated gestational triglyceridaemia and increased NEFA flux 
associated with this disease. It is interesting to note that lipolysis rates per se were not altered 
in PE and underlines the importance of insulin resistance in the etiology of the disease. There 
was borderline higher HSL expression in PE which is consistent with the observation that 
increased late gestation lipolysis is associated with a high third trimester HSL mRNA 
expression to LPL activity ratio in rats20. Our data also show that maternal booking BMI is 
not an important determinant of late gestation ex vivo adipocyte lipolytic function. In PE, 
SAT adipocyte diameter was inversely associated with insulin sensitivity but there was no 
significant difference in adipocyte diameters between PE and controls. However, there was a 
difference in size distribution between adipocyte populations from healthy and PE pregnancy 
with PE having a significantly larger proportion of small adipocytes. This is consistent with 
observations in the non-pregnant that insulin resistance is associated with a greater proportion 
of small adipose cells21. It has previously been observed that adipocyte diameter is higher in 
late gestation compared to early gestation22. Our data might suggest that there may be a 
failure in the adipocyte hypertrophic response to pregnancy in PE which could result in 
alterations of cell function and reduced capacity to store NEFA in PE pregnancy. There was a 
lower placental lactogen concentration in PE in the current study  in contrast to an earlier 
report23. This discrepancy could be due to the fact that the present study groups were matched 
for BMI.  Placental lactogen was associated with VAT, but not SAT, FCISI.  This 
information along with published data suggesting that placental lactogen can directly 
stimulate adipose tissue lipolysis24 and may induce leptin resistance25 in pregnancy makes 
this hormone an unlikely candidate for mediating the increase in SAT insulin resistance in 
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PE. TNF± has been suggested to attenuate the anti-lipolytic effect of insulin via ceramide 
signalling26 and TNF± has been shown to be a predictor of insulin resistance in pregnancy27. 
However, regression modelling found no evidence that maternal plasma TNF± levels were 
associated with either VAT or SAT insulin resistance in healthy pregnancy. TNF± was 
positively associated with SAT basal lipolysis, but this may be a marker of more “active” 
inflamed adipose tissue rather than a direct indication of regulation of lipolysis. 
 
Third trimester healthy control SAT adipocytes had higher lipolysis rates than VAT 
adipocytes, but this was not independent of larger SAT cell size. These observations are 
contrary to what is observed in non-pregnant individuals where VAT lipolysis is greater than 
SAT28. This suggests that pregnancy is associated with alterations in adipocyte lipolytic 
function and that SAT is a potential source, especially when total fat depot mass is taken into 
account, of the increased NEFA flux in healthy pregnancy that is physiologically required to 
provide fatty acids for placental transport and maternal metabolism5. Higher SAT lipolysis 
rates were more apparent for total rather than net lipolysis measurements resulting in lower 
SAT NEFA to glycerol ratios. This suggests that a greater degree of fatty acid reuptake 
occurs in SAT consistent with observations in non-pregnant SAT29. The ability to recycle 
fatty acids may provide greater flexibility for the SAT adipocyte to balance both its fat 
accrual and NEFA production functions in pregnancy. In SAT, the lower the basal lipolysis 
of the adipocyte, the higher the susceptibility to stimulation by catecholamines. This suggests 
that women with lower lipolysis rates in pregnancy may have an inherent metabolic 
flexibility towards lipolytic stimuli and respond more effectively to ‘stressful’ stimuli. We 
observed that SAT adipocyte total lipolysis insulin sensitivity inversely associated with 
plasma estradiol. Estradiol (or associated downstream responses) may thus be responsible for 
at least some of the physiological insulin resistance of healthy pregnancy30. Lower expression 
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levels of the insulin receptor in SAT may also play a part in a decreased regulation of 
lipolytic activity by insulin in pregnancy. 
 
There are regional differences in adipocyte function in pregnancy. VAT adipocytes were 
smaller, less lipolytic and had a trend towards lower insulin sensitivity after correction for 
cell size than SAT. Maternal plasma estradiol was inversely associated with VAT insulin 
sensitivity. Maternal systemic insulin resistance, assessed by HOMA, was also inversely 
associated while placental lactogen and leptin were positively associated. Potentially a 
balance between the pregnancy hormones estradiol and placental lactogen may regulate VAT 
adipocyte function in pregnancy. VAT, but not SAT, adipocyte insulin sensitivity was 
inversely associated with maternal triglycerides thereby linking VAT function with systemic 
insulin resistance. The relationship between VAT insulin resistance and plasma triglyceride is 
consistent with observations in non-pregnant VAT31, 32.  Visceral fat is drained by the portal 
vein and increased NEFA have direct effects on liver function including increased 
triglyceride secretion in very low density lipoprotein (VLDL)33.  The lower ADRB3 mRNA 
expression in VAT may render adipocytes less responsive to ² -adrenergic stimulated lipolysis 
than SAT. These data contrast with previous reports of enhanced ² 3-adrenergic function in 
VAT in the non-pregnant28 and might suggest a gestational alteration in VAT function.  
Lower LPL mRNA expression in VAT may reflect diversion of the gestational accrual of fat 
to SAT. However LPL is recognised as being regulated post-translationally34 and changes in 
mRNA expression should be interpreted with caution. The long form of the leptin receptor 
was expressed in VAT but not in SAT suggesting that leptin signalling may play a larger role 
in VAT than SAT, adipocyte function.  
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The strength of our data is the direct measurement of adipocyte lipolytic function in 
combination with plasma hormone measurements. Comparison between adipose depots was 
strengthened by paired data, PE and control groups were matched for BMI to ascertain 
obesity-independent effects and all women were non-labouring. There were limitations to our 
study. The PE sample size was small and we are unable to comment on adipocyte function at 
early gestations. Furthermore PE adipose biopsies were collected at 3 weeks earlier gestation 
than controls. Isoproterenol is a non-selective adrenoceptor agonist and use of selective 
agonists may provide further information. It is not clear to what extent our observations in a 
closed in vitro system reflect in vivo lipolysis by adipocytes where newly released NEFA 
may be rapidly removed by the circulation. Comparison of non-pregnant and pregnant SAT 
and VAT lipolytic activity is required to address which differences reflect adaptation to 
pregnancy per se. 
 
Perspectives 
Adipocyte function adapts to pregnancy and in the third trimester SAT is likely to be the 
adipose tissue depot that contributes most fatty acids to generate the physiological 
hypertriglyceridaemia of pregnancy. In PE, SAT insulin sensitivity is lower and the resulting 
exaggerated NEFA flux may contribute to ectopic fat accumulation and lipotoxic 
pathological pathways. Increasing adipocyte insulin sensitivity may be a potential strategy for 
slowing or reversing the development of PE. While pharmacological agents such as 
thiazolidenediones are inappropriate for use in pregnancy, plant extracts can increase insulin 
sensitivity of 3T3L1 adipocytes in culture35 and there is future potential for mimicking effects 
of adiponectin in adipocytes36. 
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Figure 1. Maternal adipose tissue gene expression in the healthy cohort. Subcutaneous 
adipose tissue (SAT, n=26) and visceral adipose tissue (VAT, n=23) gene expression relative 
to a control gene (PPIA). Expression of adrenoceptors A2A, B1, B2 and B3 (ADRA2A, 
ADRB1, ADRB2, ABRB3), hormone sensitive lipase (LIPE), adipose triglyceride lipase 
(PNPLA2), lipoprotein lipase (LPL), insulin receptor (INSR), leptin (LEP) and leptin receptor 
short (LEPR) and long (LEPR(long)) is shown. *Significant differences between SAT and 
VAT by paired t test on square root transformed data. 
Figure 2. Maternal adipose tissue gene expression in women with preeclampsia and 
matched controls. A) Subcutaneous adipose tissue (SAT) and B) visceral adipose tissue 
(VAT) from PE (n=13) and control (n=26) pregnancies gene expression relative to a control 
gene (PPIA). Expression of adrenoceptors A2A, B1, B2 and B3 (ADRA2A, ADRB1, ADRB2, 
ABRB3), hormone sensitive lipase (LIPE), adipose triglyceride lipase (PNPLA2), lipoprotein 
lipase (LPL), insulin receptor (INSR), leptin (LEP) and leptin receptor short (LEPR) and long 
(LEPR(long)) is shown. *Significant differences between PE and control by two sample t test 
on square root transformed data. 
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Table 1. Characteristics of healthy cohort, PE cases and matched controls. Blood 
pressure refers to booking values. All continuous values are expressed as mean and standard 
deviation (*median and interquartile range) and categorical variables as number (percent). 
Comparisons between PE and control women were carried out by two sample t test, on †log 
or ‡square root transformed data if necessary, except *Mann-Whitney and **chi-squared test. 
 
 Healthy 
cohort 
(n=31) 
Controls 
(n=26) 
PE 
(n=13) 
P value 
PE vs 
Controls 
Demographic data     
Age (years) 30.9 (5.4) 30.7 (5.3) 31.1 (6.3) 0.84 
BMI (kg/m2)† 28.9 (5.2) 29.6 (5.4) 31.1 (8.3) 0.72 
Smokers, number (%)** 3 (10.7) 2 (7.6) 2 (15.4) 0.40 
DEPCAT* 6 (4-7) 5 (4-6) 6 (4-7) 0.18 
Gestation at delivery (weeks)       38.9 (1.3) 38.8 (1.3) 35.6 (3.2) 0.004 
Primigravidae, number (%)** 6 (19.4) 5 (19.2) 7 (53.8) 0.029 
Systolic pressure (mmHg) 115 (14) 116 (15) 127 (14) 0.029 
Diastolic pressure (mmHg) 70 (8) 70 (9) 78 (9) 0.010 
Birthweight (g) 3485 (546) 3525 (554) 2330 (926) 0.001 
Birthweight centile 60 (28) 62 (29) 26 (33) 0.004 
Biochemical data     
Total cholesterol (mmol/L) 6.32 (1.08) 6.24 (1.01) 6.41 (1.45) 0.71 
Triglyceride (mmol/L)† 2.63 (0.59) 2.56 (0.59) 3.73 (2.36) 0.035 
HDL cholesterol (mmol/L) 1.84 (0.34) 1.84 (0.36) 1.71 (0.42) 0.33 
NEFA (mmol/L)‡ 0.42 (0.21) 0.39 (0.19) 0.58 (0.24) 0.011 
Glucose (mmol/L) 4.74 (0.73) 4.72 (0.42) 5.31 (1.24) 0.12 
Insulin (mU/L)† 13 (14) 11 (7) 17 (13) 0.21 
HOMA† 3.1 (4.9) 2.4 (1.9) 4.3 (3.8) 0.16 
Leptin (mg/mL)† 46 (22) 50 (20) 85 (42) 0.070 
Adiponectin (ug/mL) 9.5 (3.8) 9.1 (3.6) 9.0 (4.8) 0.94 
IL-6 (pg/mL)† 3.2 (2.1) 3.4 (2.3) 3.8 (3.2) 0.76 
TNF alpha (pg/mL)† 1.2 (0.6) 1.2 (0.6) 1.5 (0.7) 0.23 
CRP (mg/L)† 5.5 (4.4) 5.9 (4.7) 23.5 (55.5) 0.81 
Progesterone (ng/mL)† 266 (86) 247 (85) 409 (391) 0.33 
Estradiol (ng/mL) 18.6 (8.5) 17.6 (6.9) 11.7 (2.6) 0.058 
Placental lactogen (ug/mL) 11.8 (2.5) 11.7 (2.4) 8.3 (4.8) 0.030 
SAT cell size (um) 109 (11) 113 (7) 110 (11) 0.44 
VAT cell size (um) 86 (14) 90 (11) 87 (16) 0.64 
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Table 2. Lipolysis in subcutaneous and visceral adipose tissue (SAT and VAT) from 
healthy pregnancy. Isoproterenol and insulin were at 200nM and 10nM respectively. 
Lipolysis rates were corrected for cell number and expressed as mmol/L/ug DNA. Relative 
lipolysis represents the degree of stimulation by isoproterenol and the degree of suppression 
by insulin and was calculated as a percentage of basal release of NEFA or glycerol. Fat cell 
insulin sensitivity index (FCISI) was calculated as the percentage inhibition of isoproterenol-
stimulated lipolysis by insulin. Means (standard deviations) are shown. Differences between 
SAT and VAT were tested by paired t-test on †log or ‡square root transformed data if 
necessary. 
 
Treatment Total Lipolysis 
(Glycerol release) 
Net Lipolysis  
(NEFA release) 
 SAT 
(n=31) 
VAT 
(n=31) 
P SAT 
(n=31) 
VAT 
(n=31) 
P 
Lipolysis  rates (mmol/L/ug DNA) 
Basal 0.12 (0.09) 0.08 (0.08) 0.005† 0.40 (0.28) 0.25 (0.29) 0.026‡ 
Isoproterenol 0.29 (0.11) 0.19 (0.10) <0.001† 0.80 (0.42) 0.62 (0.60) 0.080‡ 
Insulin 0.13 (0.10) 0.08 (0.07) 0.001† 0.25 (0.14) 0.20 (0.24) 0.14‡ 
Isoproterenol 
plus insulin 
0.26 (0.15) 0.17 (0.11) 0.003† 0.60 (0.33) 0.52 (0.50) 0.22‡ 
Relative lipolysis (%) 
Stimulation  
of basal by 
isoproterenol 
240 (216) 337 (479) 0.94† 152 (121) 237 (184) 0.048‡ 
Inhibition of 
basal by 
insulin 
-28 (93) -40 (168) 0.41† 26 (27) 9 (44) 0.086 
FCISI 21 (66) 88 (552) 0.68† 
 
88 (135) 10 (153) 0.046 
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Table 3. Lipolysis in subcutaneous and visceral adipose tissue (SAT and VAT) from 
women with preeclampsia and BMI-matched controls. Isoproterenol and insulin were at 
200nM and 10nM respectively. Lipolysis rates were corrected for cell number and expressed 
as mmol/L/ug DNA. Relative lipolysis represents the degree of stimulation by isoproterenol 
and the degree of suppression by insulin and was calculated as a percentage of basal release 
of NEFA or glycerol. Fat cell insulin sensitivity index (FCISI) was calculated as the 
percentage inhibition of isoproterenol-stimulated lipolysis by insulin. Means (standard 
deviations) are shown. Differences between SAT and VAT were tested by two sample t-test 
on ¶untransformed †log or ‡square root transformed data if necessary (total stated before net 
lipolysis). 
Treatment  SAT Total Lipolysis 
(Glycerol release) 
SAT Net Lipolysis  
(NEFA release) 
 Control 
(n= 26) 
PE 
(n=13) 
P Control 
(n=26) 
PE 
(n=13) 
P 
Lipolysis  rates (umol/L/ug DNA) 
Basal†,‡ 119 (98) 168 (154) 0.67 397 (306) 494 (407) 0.45 
Isoproterenol†,‡ 270 (111) 330 (216) 0.75 779 (430) 961 (730) 0.50 
Insulin†,‡ 108 (62) 170 (159) 0.41 229 (144) 372 (420) 0.22 
Isoproterenol 
plus insulin†,‡ 
231 (114) 331 (231) 0.33 595 (333) 849 (672) 0.27 
Relative lipolysis (%) 
Stimulation  of 
basal by 
isoproterenol†,‡ 
251 (225) 249 (321) 0.70 151 (119) 136 (146) 0.69 
Inhibition of 
basal by 
insulin¶,‡ 
-19 (57) -40 (111) 0.48 30 (26) 20 (29) 0.31 
FCISI¶,‡ 
 
25 (44) -43 (140) 0.23 65 (102) 13 (48) 0.036 
Treatment VAT Total Lipolysis 
(Glycerol release) 
 VAT Net Lipolysis  
(NEFA release) 
 Control 
(n=25) 
PE 
(n=13) 
P Control 
(n=25) 
PE 
(n=13) 
P 
Lipolysis  rates (umol/L/ug DNA) 
Basal†,‡ 78 (72) 103 (77) 0.33 267 (311) 226 (186) 0.79 
Isoproterenol†,‡ 205 (101) 190 (119) 0.53 709 (636) 442 (312) 0.10 
Insulin†,‡ 77 (63) 109 (80) 0.19 227 (263) 193 (162) 0.83 
Isoproterenol†,‡ 
plus insulin 
189 (109) 205 (104) 0.56 602 (524) 405 (260) 0.18 
21 
 
Relative lipolysis (%) 
Stimulation  of 
basal by 
isoproterenol†,‡ 
393 (517) 390 
(1129) 
0.15 256 (179) 155 (184) 0.092 
Inhibition of 
basal by 
insulin ¶,‡ 
-45 (187) -29 (93) 0.41 5 (40) 9 (19) 0.68 
FCISI ¶,‡ 1 (59) 183 (607) 0.35 33 (76) -2 (53) 0.11 
 
  
22 
 
References 
1. Goldberg GR, Prentice AM, Coward WA, Davies HL, Murgatroyd PR, Wensing C, 
Black AE, Harding M, Sawyer M. Longitudinal assessment of energy expenditure in 
pregnancy by the doubly labeled water method. The American journal of clinical 
nutrition. 1993;57:494-505. 
2. Okereke NC, Huston-Presley L, Amini SB, Kalhan S, Catalano PM. Longitudinal 
changes in energy expenditure and body composition in obese women with normal 
and impaired glucose tolerance. Am J Physiol Endocrinol Metab. 2004;287:E472-479. 
3. Kopp-Hoolihan LE, van Loan MD, Wong WW, King JC. Fat mass deposition during 
pregnancy using a four-component model. J Appl Physiol. 1999;87:196-202. 
4. Pipe NG, Smith T, Halliday D, Edmonds CJ, Williams C, Coltart TM. Changes in fat, 
fat-free mass and body water in human normal pregnancy. British journal of 
obstetrics and gynaecology. 1979;86:929-940. 
5. Diderholm B, Stridsberg M, Ewald U, Lindeberg-Norden S, Gustafsson J. Increased 
lipolysis in non-obese pregnant women studied in the third trimester. BJOG : an 
international journal of obstetrics and gynaecology. 2005;112:713-718. 
6. Ehrenberg HM, Huston-Presley L, Catalano PM. The influence of obesity and 
gestational diabetes mellitus on accretion and the distribution of adipose tissue in 
pregnancy. American journal of obstetrics and gynecology. 2003;189:944-948. 
7. Sohlstrom A, Wahlund LO, Forsum E. Total body fat and its distribution during 
human reproduction as assessed by magnetic resonance imaging. Basic life sciences. 
1993;60:181-184. 
8. Kinoshita T, Itoh M. Longitudinal variance of fat mass deposition during pregnancy 
evaluated by ultrasonography: The ratio of visceral fat to subcutaneous fat in the 
abdomen. Gynecologic and obstetric investigation. 2006;61:115-118. 
9. Einstein FH, Fishman S, Muzumdar RH, Yang XM, Atzmon G, Barzilai N. Accretion 
of visceral fat and hepatic insulin resistance in pregnant rats. Am J Physiol Endocrinol 
Metab. 2008;294:E451-455. 
10. Jarvie E, Hauguel-de-Mouzon S, Nelson SM, Sattar N, Catalano PM, Freeman DJ. 
Lipotoxicity in obese pregnancy and its potential role in adverse pregnancy outcome 
and obesity in the offspring. Clinical science (London, England : 1979). 
2010;119:123-129. 
11. Bartha JL, Marin-Segura P, Gonzalez-Gonzalez NL, Wagner F, Aguilar-Diosdado M, 
Hervias-Vivancos B. Ultrasound evaluation of visceral fat and metabolic risk factors 
during early pregnancy. Obesity (Silver Spring, Md.). 2007;15:2233-2239. 
12. Ijuin H, Douchi T, Nakamura S, Oki T, Yamamoto S, Nagata Y. Possible association 
of body-fat distribution with preeclampsia. J Obstet Gynaecol Res. 1997;23:45-49. 
13. Sattar N, Clark P, Holmes A, Lean ME, Walker I, Greer IA. Antenatal waist 
circumference and hypertension risk. Obstetrics and gynecology. 2001;97:268-271. 
14. Zhang S, Folsom AR, Flack JM, Liu K. Body fat distribution before pregnancy and 
gestational diabetes: Findings from coronary artery risk development in young adults 
(cardia) study. BMJ (Clinical research ed.). 1995;311:1139-1140. 
15. Sattar N, Gaw A, Packard CJ, Greer IA. Potential pathogenic roles of aberrant 
lipoprotein and fatty acid metabolism in pre-eclampsia. British journal of obstetrics 
and gynaecology. 1996;103:614-620. 
16. Cottrell EC, Mercer JG. Leptin receptors. Handbook of experimental pharmacology. 
2012:3-21. 
17.  Lipid research clinics program. Lipid and lipoprotein analysis. Manual of laboratory 
operations vol. 1 Publication No. 75-628. 1974.  
23 
 
18. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee 
CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD. Lipoprotein-
associated phospholipase a2 as an independent predictor of coronary heart disease. 
West of scotland coronary prevention study group. The New England journal of 
medicine. 2000;343:1148-1155. 
19. Rodbell M. Metabolism of isolated fat cells. I. Effects of hormones on glucose 
metabolsim and lipolysis. The Journal of biological chemistry. 1964;239:375-380. 
20. Martin-Hidalgo A, Holm C, Belfrage P, Schotz MC, Herrera E. Lipoprotein lipase 
and hormone-sensitive lipase activity and mrna in rat adipose tissue during pregnancy. 
Am J Physiol. 1994;266:E930-935. 
21. McLaughlin T, Lamendola C, Coghlan N, Liu TC, Lerner K, Sherman A, Cushman 
SW. Subcutaneous adipose cell size and distribution: Relationship to insulin 
resistance and body fat. Obesity (Silver Spring, Md.). 2012:epub ahead of print. 
22. Resi V, Basu S, Haghiac M, Presley L, Minium J, Kaufman B, Bernard S, Catalano P, 
Hauguel-de Mouzon S. Molecular inflammation and adipose tissue matrix remodeling 
precede physiological adaptations to pregnancy. Am J Physiol Endocrinol Metab. 
2012;303:E832-840. 
23. Murai JT, Muzykanskiy E, Taylor RN. Maternal and fetal modulators of lipid 
metabolism correlate with the development of preeclampsia. Metabolism: clinical and 
experimental. 1997;46:963-967. 
24. Williams C, Coltart TM. Adipose tissue metabolism in pregnancy: The lipolytic effect 
of human placental lactogen. British journal of obstetrics and gynaecology. 
1978;85:43-46. 
25. Ladyman SR, Augustine RA, Grattan DR. Hormone interactions regulating energy 
balance during pregnancy. Journal of neuroendocrinology. 2010;22:805-817. 
26. Mei J, Holst LS, Landstrom TR, Holm C, Brindley D, Manganiello V, Degerman E. 
C(2)-ceramide influences the expression and insulin-mediated regulation of cyclic 
nucleotide phosphodiesterase 3b and lipolysis in 3t3-l1 adipocytes. Diabetes. 
2002;51:631-637. 
27. Kirwan JP, Hauguel-De Mouzon S, Lepercq J, Challier JC, Huston-Presley L, 
Friedman JE, Kalhan SC, Catalano PM. Tnf-alpha is a predictor of insulin resistance 
in human pregnancy. Diabetes. 2002;51:2207-2213. 
28. Van Harmelen V, Lonnqvist F, Thorne A, Wennlund A, Large V, Reynisdottir S, 
Arner P. Noradrenaline-induced lipolysis in isolated mesenteric, omental and 
subcutaneous adipocytes from obese subjects. International journal of obesity and 
related metabolic disorders : journal of the International Association for the Study of 
Obesity. 1997;21:972-979. 
29. Hammond VA, Johnston DG. Substrate cycling between triglyceride and fatty acid in 
human adipocytes. Metabolism: clinical and experimental. 1987;36:308-313. 
30. Catalano PM, Tyzbir ED, Roman NM, Amini SB, Sims EA. Longitudinal changes in 
insulin release and insulin resistance in nonobese pregnant women. American journal 
of obstetrics and gynecology. 1991;165:1667-1672. 
31. Andersson DP, Lofgren P, Thorell A, Arner P, Hoffstedt J. Visceral fat cell lipolysis 
and cardiovascular risk factors in obesity. Horm Metab Res. 2011;43:809-815. 
32. Zierath JR, Livingston JN, Thorne A, Bolinder J, Reynisdottir S, Lonnqvist F, Arner 
P. Regional difference in insulin inhibition of non-esterified fatty acid release from 
human adipocytes: Relation to insulin receptor phosphorylation and intracellular 
signalling through the insulin receptor substrate-1 pathway. Diabetologia. 
1998;41:1343-1354. 
24 
 
33. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free 
fatty acids and insulin in the acute control of very low density lipoprotein production 
in humans. The Journal of clinical investigation. 1995;95:158-166. 
34. Tornvall P, Olivecrona G, Karpe F, Hamsten A, Olivecrona T. Lipoprotein lipase 
mass and activity in plasma and their increase after heparin are separate parameters 
with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol. 
1995;15:1086-1093. 
35. Kalekar SA, Munshi RP, Bhalerao SS, Thatte UM. Insulin sensitizing effect of 3 
indian medicinal plants: An in vitro study. Indian journal of pharmacology. 
2013;45:30-33. 
36. Fu Y, Luo N, Klein RL, Garvey WT. Adiponectin promotes adipocyte differentiation, 
insulin sensitivity, and lipid accumulation. Journal of lipid research. 2005;46:1369-
1379. 
 
  
